Asia Pacific Endothelial Dysfunction Market Forecast to 2028 - Regional Analysis - by Cause (Hypertension, Diabetes, Hypercholestrolaemia, Bechet's Disease, Obesity, and Others), Test Type [Invasive Tests and Non-Invasive Tests (Flow Mediated Dilatory, Pe

Asia Pacific Endothelial Dysfunction Market Forecast to 2028 - Regional Analysis - by Cause (Hypertension, Diabetes, Hypercholestrolaemia, Bechet's Disease, Obesity, and Others), Test Type [Invasive Tests and Non-Invasive Tests (Flow Mediated Dilatory, Peripheral Arterial Tonometry (PAT), Venous Occlusion Pletismography, Circulating Markers, and Others)], and End User (Hospitals, Ambulatory Surgery Centers, Specialty Clinics, and Others)

The Asia Pacific endothelial dysfunction market is expected to grow from US$ 304.48 million in 2022 to US$ 405.51 million by 2028. It is estimated to grow at a CAGR of 4.9% from 2022 to 2028.

Rising Usage of Novel Biomarkers and Therapeutic Strategies Fuels Asia Pacific Endothelial Dysfunction Market

Examining endothelial function can improve risk stratification, improve early disease detection, and assess vascular response to therapeutic interventions. There are studies to understand the pathophysiological mechanisms underlying endothelial dysfunction and atherosclerosis progression in a better way and identify new biomarkers and therapeutic strategies to prevent endothelial dysfunction and atherosclerosis to reduce the risk of developing coronary artery disease (CAD) and related complications. Using liquid biopsies and new molecular biology techniques has enabled the identification of a growing list of molecular and cellular markers of endothelial dysfunction that have provided insight into the molecular basis of atherosclerosis as well as potential biomarkers and therapeutic targets for the prevention and treatment of atherosclerosis and CAD.

Research on biomarkers and their clinical application has increased exponentially over the last few decades. Invaluable insight into the pathophysiology of atherosclerosis and the development of novel therapies have been provided by systemic biomarkers. Endothelial dysfunction and inflammation play a central role in the development and progression of CAD. Inflammatory mediators are secreted by inflammatory and vascular cells in atherosclerotic plaque or by organs such as the liver or adipose tissue.

Asia Pacific Endothelial Dysfunction Market Overview

The endothelial dysfunction market in Asia Pacific is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The growth of the market in the region is attributed to the increasing cases of endothelial dysfunction with the rising incidence of CVD, hypertension, diabetes, and chronic diseases, coupled with the growing aging population. In addition, the market is driven by increasing investments in diagnostics techniques by the respective country governments, resulting in advancements in diagnostics methods.

Asia Pacific Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)

Asia Pacific Endothelial Dysfunction Market Segmentation

The Asia Pacific endothelial dysfunction market is segmented into cause, test type, end user, and country.

Based on cause, the Asia Pacific endothelial dysfunction market is segmented into hypertension, hypercholesterolaemia, obesity, diabetes, Behcet's disease, and others. The hypertension segment registered the largest Asia Pacific endothelial dysfunction market share in 2022.

Based on test type, the Asia Pacific endothelial dysfunction market is segmented into invasive test and non-invasive test. The invasive test segment held a larger Asia Pacific endothelial dysfunction market share in 2022. The non-invasive test segment is further subsegmented into flow mediated dilatory, peripheral arterial tonometry (PAT), venous occlusion pletismography, circulating markers, and others.

Based on end user, the Asia Pacific endothelial dysfunction market has been categorized into hospitals, diagnostic centers, clinics, and others. The hospitals segment held the largest Asia Pacific endothelial dysfunction market share in 2022.

Based on country, the Asia Pacific endothelial dysfunction market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific endothelial dysfunction market in 2022.

ZOLL Medical Corp, Sphingo Tec GmbH, Perimed AB, and Medizinische Messtechnik GmbH are some of the leading companies operating in the endothelial dysfunction market in the region.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific endothelial dysfunction market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific endothelial dysfunction market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the endothelial dysfunction market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution